Found 33 clinical trials
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US
Phase 2 single-arm, multi-cohort study to determine the efficacy and safety of JCAR017 (autologous T cells expressing anti-CD19 chimeric antigen receptor) in adult subjects with aggressive B-NHL (diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central …
- 1875 views
- 26 Mar, 2021
- 15 locations
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US Spanish
Phase 2 single-arm, multi-cohort study to determine the efficacy and safety of JCAR017 (autologous T cells expressing anti-CD19 chimeric antigen receptor) in adult subjects with aggressive B-NHL (diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central …
- 268 views
- 26 Mar, 2021
- 16 locations
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. A donor stem cell transplant may replace the patient's immune cells …
- 0 views
- 07 Nov, 2020
- 1 location
High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement
CNS involvement at diagnosis or relapse. Selected drugs, with a well-documented anti-lymphoma activity, will be administered at high doses to increase blood-brain barrier penetration and CNS
- 4 views
- 07 Nov, 2020
- 1 location
Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma
The protocol aims at reducing transplant toxicity and mortality in patients with multiple myeloma.
- 4 views
- 07 Nov, 2020
- 1 location
Azithromycin in Post Diarrheal Haemolytic and Uremic Syndrome
Post diarrheal hemolytic and uremic syndrome (D+HUS) is the first etiology of acute renal failure in children less than 5 years old in France. Previous works highlighted a mortality rate of 2 % and a prevalence of renal sequelae at one year after D+HUS onset in 25 % of patients …
- 0 views
- 23 Jan, 2021
- 1 location
A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours
Despite some encouraging data, systemic treatment of CNS metastases from solid tumors remains experimental. Better knowledge on the evolving epidemiology and biology of BM are key elements for the development of new treatment strategies and identification of promising therapeutic targets for new compounds. Further biological findings may help to better …
- 0 views
- 20 Jul, 2021
- 17 locations
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Children with a neuroblastoma diagnose and central nervous system (CNS)/leptomeningeal metastases will be given up to 2 rounds of intracerebroventricular treatment with a radiolabelled monoclonal antibody, 131I-omburtamab to evaluate efficacy and safety
- 48 views
- 28 Jun, 2021
- 14 locations
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Primary objectives: Randomization R1, all patients eligible: To examine, whether the cumulative incidence of relapses with involvement of the CNS (CNS relapse, pCICR) can be decreased by a modified induction therapy including dexamethasone (experimental arm) instead of prednisone (standard arm) Randomization R2, only patients with high risk LBL eligible: to …
- 0 views
- 19 Jun, 2021
- 224 locations
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma
This open-label Phase 2 study will evaluate the safety and efficacy of modified T cells (JCAR017) administered to adult patients with aggressive B-cell non-Hodgkin lymphoma (NHL). The study will also help determine how long the modified T cells stay in the patient's body. Furthermore, changes in the patient's quality of …
- 191 views
- 25 Jun, 2021
- 29 locations